Biolinerx ltd. (BLRX)
CashFlow / Yearly
Dec'17Dec'16Dec'15
CASH FLOWS - OPERATING ACTIVITIES
Comprehensive loss for the period

-24,352

-15,841

-14,400

Adjustments required to reflect net cash used in operating activities (see appendix below)

3,805

1,328

232

Net cash used in operating activities

-20,547

-14,513

-14,168

CASH FLOWS - INVESTING ACTIVITIES
Long-term investment

-1,000

0

0

Investments in short-term deposits

-44,016

-32,982

-63,130

Maturities of short-term deposits

-33,327

-42,334

-50,083

Maturities of restricted deposits

0

0

-166

Purchase of property and equipment

338

52

2,683

Purchase of intangible assets

3,900

3

36

Net cash provided by (used in) investing activities

-15,927

9,297

-15,600

CASH FLOWS - FINANCING ACTIVITIES
Issuances of share capital, net

38,773

2,183

29,053

Proceeds of bank loan

0

0

467

Repayments of bank loan

93

93

31

Net cash provided by financing activities

38,680

2,090

29,489

INCREASE IN CASH AND CASH EQUIVALENTS

2,206

-3,126

-279

EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS

435

51

33

Adjustments required to reflect net cash used in operating activities:
Income and expenses not involving cash flows:
Depreciation and amortization

481

482

441

Long-term prepaid expenses

-9

6

-9

Exchange differences on cash and cash equivalents

-435

-51

-33

Gain on adjustment of warrants to fair value

127

-207

-1,292

Share-based compensation

1,508

1,075

1,152

Interest and exchange rate differences on short-term deposits

-530

-387

-182

Interest and linkage differences on bank loan

0

-1

1

Warrant issuance costs

17

0

0

Total income and expense not involving cash flows

1,159

917

78

Changes in operating asset and liability items:
Increase in prepaid expenses and other receivables

415

-42

42

Increase (decrease) in accounts payable and accruals

3,061

369

196

Total Change in operating asset and liability

2,646

411

154

Total Adjustments required to reflect net cash used in operating acivities

3,805

1,328

232

Supplementary information on interest received in cash

494

453

173

Supplementary non-cash investment

2,985

0

0